AUTHORS
Naomi Marali Xiao, Lisa Avery2, Christine Chen, MHPE, MD, FRCPC3, Anca Prica, MD4, Danielle Rodin, MD5, Sita Bhella, MD6, Tomohiro Aoki, MD, PhD7, Robert Kridel, MD8, Vishal Kukreti, MD9, Massimiliano Marinoni, MD10, Abi Vijenthira, MD, MS11, Chloe Yang, MD12, Mahmood Aminilari, PhD13, David Hodgson, MD, MPH14, Badr Id Said, MD, MSc15, Woodrow Wells, MD16, Michael Crump, MD17, Inna Y Gong, MD, PhD18, John Kuruvilla, MD19
AFFILIATIONS
2 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
4 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
11 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
12 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
13 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
14 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
15 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
16 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
17 University of Toronto, Toronto, Ontario, Canada
19 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
ABSTRACT
Background
Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy is now approved as both a second-line (2L) and third-line-or-later (3L+) treatment for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). This expansion has broadened the eligible population to include patients who may differ from the heavily pretreated cohorts in which existing risk models were developed. CAR-HEMATOTOX (HT) and InflaMix are validated baseline risk scores in patients receiving anti-CD19 CAR-T. HT predicts prolonged cytopenias, infections, and survival using hematopoietic reserve and inflammation markers. InflaMix classifies patients into inflammatory versus non-inflammatory clusters using inflammatory biomarker panels, available as a 6-laboratory (IM6) or 14-laboratory (IM14) version and is predictive of toxicity and survival. Whether the distribution of risk categories and their prognostic performance are consistent in the 2L setting is not well characterized. We evaluated HT and InflaMix profiles by treatment line and assessed their associations with treatment outcomes.
Methods
We conducted a retrospective cohort study of patients with R/R LBCL receiving anti-CD19 CAR-T therapy at Princess Margaret Cancer Centre (June 2020-February 2026). Patients were stratified according to receipt of 2L versus 3L+ CAR-T. Pre-lymphodepletion and pre-infusion laboratory values were used to calculate HT and InflaMix scores (IM14 calculated without IL-6, IL-10, and TNFα as these markers are not routinely available). Baseline characteristics and biomarkers were compared between treatment lines using chi-squared/Fisher's exact or Wilcoxon rank-sum. Cox models evaluated associations between HT/InflaMix stratification and progression-free survival (PFS) and overall survival (OS), adjusting for International Prognostic Index (IPI), CAR-T product, and treatment line. Associations between HT risk/InflaMix stratification and cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) were assessed using chi-squared or Fisher’s exact tests.
Results
The cohort comprised 248 patients: (50 [20%] 2L, 198 [80%] 3L+ CAR-T; 82% axi-cel, 14% tisa-cel, 5% liso-cel; 38% female, median age 62 [range 20-84]; 55% DLBCL, 23% HGBL, 22% tNHL). Age, sex, histology, and IPI were similar across treatment lines. HT risk did not differ by line (high-risk 38% vs 45%; p=0.4), nor did IM6-inflammatory (4.0% vs 9.9%; p=0.3) or IM14-inflammatory proportions (24% vs 17%; p=0.3). However, 3L+ patients had lower platelet (136 vs 205 x109/L, p<0.001) and WBC counts (2.20 vs 3.25 x109/L, p<0.001), and higher CRP (1.10 vs 0.40 mg/dL, p=0.002) versus 2L.
Patients with low HT had improved PFS (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.48-0.96, p=0.03) and OS (HR 0.62, 95% CI 0.41-0.93, p=0.02) compared to high HT in univariable analyses. However, these associations were no longer significant after adjustment for IPI, CAR-T product, and treatment line (adjusted HR [aHR] 0.74, 95% CI 0.51-1.07, p=0.11 for PFS; aHR 0.76, 95% CI 0.49-1.16, p=0.20 for OS).
Compared to IM6-inflammatory status, non-inflammatory status was associated with improved PFS (HR 0.33, 95% CI 0.20-0.55, p<0.001) and OS (HR 0.27, 95% CI 0.16-0.47, p<0.001), and remained significant after adjustment (aHR 0.34, 95% CI 0.20-0.58, p<0.001 for PFS; aHR 0.29, 95% CI 0.16-0.51, p<0.001 for OS). IM14-non-inflammatory status showed similar univariable associations for PFS (HR 0.59, 95% CI 0.39-0.90, p=0.014) and OS (HR 0.44, 95% CI 0.28-0.69, p<0.001), which remained significant after adjustment (aHR 0.64, 95% CI 0.42-0.98, p=0.04 for PFS; aHR 0.54, 95% CI 0.34-0.87, p=0.01 for OS).
HT-high patients had higher rates of grade ≥3 CRS compared to HT-low (4.7% vs 1.5%, p=0.07) but similar rates of grade ≥3 ICANS (9.4% vs 7.5%, p=0.9). Patients with IM6- and IM14-inflammatory status also showed higher rates of grade ≥3 CRS (14% vs 1.8%, p=0.015, and 11% vs 1.0%, p=0.001, respectively) and grade ≥3 ICANS (24% vs 6.9%, p<0.001, and 20% vs 5.7%, p<0.001, respectively).
Conclusion
HT and InflaMix distributions were similar between 2L and 3L+ patients despite differences in individual markers. InflaMix remained independently associated with survival outcomes, while HT demonstrated prognostic associations in univariable analyses, supporting the use of these tools for risk stratification across 2L and 3L+ treatment lines in CAR-T therapy for R/R LBCL.
DISCLOSURES
Inna Y Gong, MD, PhD: Kite/Gilead - Honoraria